Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BIBF1120 Inhibits Lowering of FVC: BI
December 13, 2010
- NBI Takes Over Mobic Marketing from Daiichi Sankyo
December 13, 2010
- Lubiprostone Shows Favorable Safety, Tolerability in PIII: Sucampo, Abbott
December 13, 2010
- Sales of Class 1 OTC Drugs Up 8.9% in October: JSMI
December 13, 2010
- Otsuka HD's Market Capitalization to Exceed \1 Tril.
December 13, 2010
- JPMA Campaign Highlights Non-approved Drugs
December 13, 2010
- Kyorin Turns Down New Proposal from Sawai
December 13, 2010
- Daiichi Sankyo, Kitasato to Set Up Vaccine JV
December 13, 2010
- JPMA Allies with Patients' Groups for Lobbying
December 13, 2010
- Astellas Establishes Global Oncology Strategy Unit
December 13, 2010
- Ain Pharmaciez: Half-Year Sales Up 3.5% to \61.8 Bil.
December 13, 2010
- Takeda Applies for Higher Leuplin Dosage Based on Published Evidence
December 13, 2010
- MTPC Expects Fingolimod to Become Blockbuster: President Tsuchiya
December 13, 2010
- Cocokara fine Aims at Sales of ¥500 Bil. in FY2015
December 13, 2010
- Eisai Applies for SEP-190 for Insomnia
December 13, 2010
- Acotiamide to Drive Zeria's Global Business
December 13, 2010
- Early Price Settlement Unlikely: Mr Minari of Nihon Chouzai
December 13, 2010
- Kyowa Hakko Bio's Hofu Facility Complies with GMP Requirements: Korosho
December 13, 2010
- Teijin to Extend Pharma Business by Launching Feburic, Synvisc: Mr Ohyagi
December 13, 2010
- Qol to Open More Convenience Stores with Dispensing Services
December 13, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…